Knopp's dexpramipexole shows Phase II benefit in ALS
This article was originally published in Scrip
Executive Summary
Knopp Biosciences has published a Phase II study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in patients with amyotrophic lateral sclerosis (ALS), in which researchers said that they had "detected an apparent clinically significant, dose-dependent effect on both function and mortality". The data also suggest that the drug may slow down the decline in the disease.